quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·172d
PRRelease
Nautilus Biotechnology Inc. logo

Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging

NAUT· Nautilus Biotechnology Inc.
Industrials
Original source

Companies

  • NAUT
    Nautilus Biotechnology Inc.
    Industrials

Recent analyst ratings

  • Dec 5UpdateGoldman$1.75
  • Jun 27UpdateGuggenheim$6.00
  • Jun 3UpdateJefferies$3.00
  • Jan 6UpdateMorgan Stanley$8.00
  • Nov 2UpdateCowen & Co.-
  • Aug 4UpdateGoldman Sachs$10.00

Related

  • PR15d
    Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
  • PR31d
    Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
  • PR37d
    Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
  • SEC50d
    Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
  • INSIDER50d
    CEO, President, and Secretary Patel Sujal M bought $65,238 worth of shares (25,000 units at $2.61), increasing direct ownership by 0.24% to 10,366,721 units (SEC Form 4)
  • INSIDER50d
    SEC Form 4 filed by CFO and Treasurer Mowry Anna
  • INSIDER50d
    SEC Form 4 filed by Chief Scientist Mallick Parag
  • INSIDER50d
    SEC Form 4 filed by CEO, President, and Secretary Patel Sujal M
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022